CryoLife Reports Fourth Quarter and Full Year 2003 Financial
Results Reaffirms tissue processing and product revenue growth
estimate of 12 to 18% in 2004 ATLANTA, Feb. 26
/PRNewswire-FirstCall/ -- CryoLife, Inc. , a human tissue
processing and bio-surgical device company reported financial
results for the fourth quarter and year ended December 31, 2003.
The Company also reaffirmed its previously announced guidance that
tissue processing and product revenues are expected to increase 12
to 18 percent to between $66 and $70 million for the full year
2004. Revenues for the fourth quarter 2003 were $12.8 million,
compared to $12.2 million for the fourth quarter of 2002. Net loss
in the fourth quarter of 2003 was $7.2 million, compared to $5.7
million for the same period in 2002. On a fully diluted basis, loss
per common share in the fourth quarter was $0.37, compared to $0.29
for the fourth quarter of 2002. Revenues for the year ended
December 31, 2003 were $59.5 million, compared to $77.8 million in
2002. Net loss for full year 2003 was $32.3 million, compared to a
net loss of $27.8 million for full year 2002. On a fully diluted
basis, loss per common share was $1.64 for full year 2003, compared
to $1.43 for full year 2002. In the fourth quarter of 2003,
worldwide BioGlue sales increased 39 percent to $7.8 million,
compared to $5.6 million in the fourth quarter of 2002. BioGlue
revenues increased 33 percent to $27.8 million for the full year
2003, compared to $20.9 million for the sameperiod in 2002. BioGlue
revenues are expected to increase to $32 to $34 million in 2004.
BioGlue revenues for the first quarter of 2004 are expected to be
between $7.8 to $8.0 million. "We are pleased with the 33%
year-to-year sales growth of BioGlue and we expect to introduce a
new BioGlue syringe delivery device in 2004. The entire pre-filled
device is disposable and will eliminate the need for
resterilization of the dispenser," stated Steven G. Anderson,
President and CEO. "While BioGlue is the first protein hydrogel
marketed by the Company, we are also developing several other
promising products using protein hydrogel technology. These
development projects include: BioDisc, which is being developed for
use as an injectable nucleus pulposus replacement in minimally
invasive surgery for spinal disc repair; BioFoam, for rapid
hemostasis for penetrating wounds and severe trauma; and
LiquiStent, which has promise as a biological intervascular stent
that could prove to be non-thrombogenic andbiocompatible, and may
avoid a tissue response that would occlude the blood vessel." Human
tissue processing revenues were $30.8 million for the full year
2003, compared to $55.4 million for the full year 2002. Human
tissue processing revenues were $4.9 million in the fourth quarter
of 2003, compared to $6.3 million in the fourth quarter of 2002.
The Company is currently processing and distributing cardiac,
vascular, and boned and non-boned orthopaedic tissue. The Company
expects human tissue processing revenues to increase by 7 to 14
percent to between $33 and $35 million in 2004. While human tissue
processing revenues will increase in the first quarter of 2004
compared to fourth quarter of 2003, human tissue processing
revenues will be slightly below the previous guidance of $7.0 and
$7.5 million for the first quarter of 2004. Total revenues
projected for the first quarter of $14.8 to $15.5 million remains
unchanged. The Company has a comprehensive program to increase the
tissues available for distribution to patients. This program
includes recently implemented initiatives with tissue procurement
organizations, operating a newly created in-house pathology
department, and several tissue processing improvements. The Company
expects to realize the positive impact of these initiatives on
revenues beginning in the second quarter of 2004. Cardiac tissue
processing revenues were $2.8 million in the fourth quarter of
2003, compared to $3.3 million in the same period in 2002 and $17.1
million for the full year 2003, compared to $23.4 million for the
full year 2002. Vascular tissue processing revenues were $12.7
million for the full year 2003, compared to $17.8 million for the
full year 2002 and $2.0 million in the fourth quarter of
2003,compared to $2.9 million for the same period in 2002.
Orthopaedic tissue processing revenues were $1.1 million for the
full year 2003, compared to $14.1 million for the full year 2002
and $166,000 in the fourth quarter of 2003, compared to $108,000
for the same period in 2002. Selling, general, and administrative
expenses are expected to be approximately $42 to $46 million in
2004, while research and development expenses are expected to be
approximately $4 million in 2004. For the first quarter of2004, the
Company expects selling, general, and administrative expenses of
approximately $10 to $11 million, and expects research and
development expenses to be approximately $1 million. CryoLife's SG
Model #100, an arteriovenous (A-V) access device made from a bovine
ureter, is approved in Europe for use in dialysis patients. The SG
Model #100 utilizes the Company's antigen reduction technology
(ART). This patented process removes antigens from tissues, which
appears to allow the patient to receive the implant without
requiring immunosuppressant therapy. There are now over 125
patients in the U.K. and Italy with SG Model #100 A-V access device
implants who are in a clinical registry. In February 2004 the FDA
requested additional information beprovided to support CryoLife's
510k premarket notification for decellularized SG processed human
heart valves. The Company is reviewing and addressing the FDA's
requirements. Since February 2003, the Company has been processing
human tissues without the decellularized SG technology. The FDA
also completed an inspection of the Company's tissue processing
facility and made observations in a Form 483, which the Company is
addressing. The Company has made significant progress on product
liability cases, resolving or reaching agreements in principle to
resolve 22 product liability lawsuits and claims and currently has
two remaining lawsuits pending related to the 2002/2003 insurance
policy year. Other product liability lawsuits and claims are also
pending. The Company recently strengthened its financial position
after it raised net proceeds of approximately $20 million in a
private equity placement. As of February 20, 2004 the Company had
approximately $27 million in the aggregate of cash, cashequivalents
and marketable securities. Additionally, the Company expects to
receive tax refunds of approximately $2.4 million in 2004. The
Company will hold a teleconference call and live webcast today at
11:15 a.m. Eastern Time to discuss fourth quarter and year ended
December 31, 2003 results followed by a question and answer session
hosted by Steven G. Anderson, CryoLife President and Chief
Executive Officer. To listen to the live teleconference please dial
973-582-2700 a few minutes prior to 11:15 a.m. No identification
number is required. A replay of the teleconference will be
available February 26 through March 4 and can be accessed by
calling (toll free) 877-519-4471 or 973-341-3080. The
identification number for the replay is 4497182. The live webcast
can be accessed by going to the Investor Relations section of the
CryoLife web site at http://www.cryolife.com/ . Founded in 1984,
CryoLife, Inc. is a leader in the processing and distribution of
implantable living human tissues for use in cardiovascular and
vascular surgeries throughout the United States and Canada. The
Company's BioGlue(R) Surgical Adhesive is FDA approved as an
adjunct to sutures and staples for use in adult patients in open
surgical repair of large vessels and is CE marked in the European
Community and approved in Canada for use in soft tissue repair and
approved in Australia for use in vascular and pulmonary sealing and
repair. The Company also manufactures the SG Model #100 vascular
graft, which is CE marked for distribution within the European
Community. Statements made in this press release that look forward
in time or that express management's beliefs, expectations or hopes
are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These future events may
not occur as and when expected, if at all, and, together with the
Company's business, are subject to various risks and uncertainties.
These risks and uncertainties include that the Company's 2004
revenues and expenses may not meet its expectations, that demand
for CryoLife preserved tissues may not return to prior levels, the
possibility that the FDA could impose additional restrictions on
the Company's operations, require a recall, or prevent the Company
from processing and distributing tissues or manufacturing and
distributing other products, that the Company's new BioGlue syringe
delivery device and SG Model #100 bovine ureter product may not
meet expectations, that the Company's 510k application for SG
processed heart valves may require significant time and expense and
may not be cleared on a timely basis or at all, that FDA regulation
of the Company's CryoValve SG and CryoVein SG may require
significant time and expense, that the protein hydrogel products
under development may not be commercially feasible, that the
Company may not have sufficient borrowing or other capital
availability to fund its business, that present and future
litigation may be resolved only by substantial payments by the
Company in excess of available insurance coverage and amounts set
aside for products liability cases by CryoLife since the outcomes
of products liability securities class action and derivative cases
are inherently uncertain, that pending litigation cannot be settled
on terms acceptable to the Company, that the Company may not have
sufficient resources to pay punitive damages which are not covered
by insurance or liabilities in excess of available insurance, the
possibility of severe decreases inthe Company's revenues and
working capital, that to the extent the Company does not have
sufficient resources to pay the claims against it, it may be forced
to cease operations or seek protection under applicable bankruptcy
laws, changes in laws and regulations applicable to CryoLife and
other risk factors detailed in CryoLife's Securities and Exchange
Commission filings, including CryoLife's Form 10-K filing for the
year ended December 31, 2002, and the Company's other SEC filings.
The Company does not undertake to update its forward-looking
statements. Contact: Joseph T. Schepers Vice President, Corporate
Communications (770) 419-3355 CRYOLIFE, INC. (In thousands, except
per share data) Three Months Ended Year Ended December 31, December
31, 2003 2002 2003 2002 (Unaudited) (Audited) Revenues: Human
tissue preservation services $4,935 $6,299 $30,777 $55,373 Products
7,901 5,705 28,263 21,597 Distribution and grant (34) 167 492 825
Total revenues 12,802 12,171 59,532 77,795 Costs and expenses:
Human tissue preservation services 8,892 2,119 23,976 55,363
Products 2,077 1,453 7,506 10,270 General, administrative, and
marketing 7,924 15,412 53,630 47,530 Research and development 816
901 3,644 4,597 Goodwill impairment -- -- -- 1,399 Interest expense
49 149 415 692 Interest income (76) (170) (425) (895) Other
(income) expense, net (35) 310 12 273 Total costs and expenses
19,647 20,174 88,759 119,229 Loss before income taxes (6,845)
(8,003) (29,226) (41,434) Income tax expense (benefit) 399 (2,306)
3,068 (13,673) Net loss $(7,244) $(5,697) $(32,294) $(27,761) Net
loss per share: Basic $(0.37) $(0.29) $(1.64) $(1.43) Diluted
$(0.37) $(0.29) $(1.64) $(1.43) Weighted average shares
outstanding: Basic 19,729 19,526 19,684 19,432 Diluted 19,729
19,526 19,684 19,432 Revenues from: Cardiovascular $2,751 $3,283
$17,059 $23,413 Vascular 2,018 2,908 12,655 17,826 Orthopaedic 166
108 1,063 14,134 Total preservation services 4,935 6,299 30,777
55,373 BioGlue 7,757 5,590 27,784 20,898 Implantable medical
devices 144 115 479 699 Distribution and grant (34) 167 492 825
Total revenues $12,802 $12,171 $59,532 $77,795 Domestic revenues
$10,727 $10,715 $51,949 $71,188 International revenues 2,075 1,456
7,583 6,607 Total revenues $12,802 $12,171 $59,532 $77,795
CRYOLIFE, INC. Financial Highlights (In thousands) Audited Dec. 31,
Dec. 31, 2003 2002 Cash and cash equivalents, cash held in escrow,
$11,916 $24,860 and marketable securities, at market Trade
receivables, net 6,377 6,930 Other receivables, net 1,865 11,824
Deferred preservation costs, net 8,811 4,332 Inventories 4,450
4,585 Total assets 75,027 106,414 Shareholders' equity 48,338
79,800 For additional information about the company, visit
CryoLife's Web site: http://www.cryolife.com/ DATASOURCE: CryoLife,
Inc. CONTACT: Joseph T. Schepers, Vice President, Corporate
Communications of CryoLife, Inc., +1-770-419-3355 Web site:
http://www.cryolife.com/
Copyright
CryoLife (NYSE:CRY)
Historical Stock Chart
From Jun 2024 to Jul 2024
CryoLife (NYSE:CRY)
Historical Stock Chart
From Jul 2023 to Jul 2024